PMID- 33460282
OWN - NLM
STAT- MEDLINE
DCOM- 20210917
LR  - 20231107
IS  - 1615-9861 (Electronic)
IS  - 1615-9853 (Print)
IS  - 1615-9853 (Linking)
VI  - 21
IP  - 9
DP  - 2021 May
TI  - Mass spectrometric investigations of caloric restriction mimetics.
PG  - e2000121
LID - 10.1002/pmic.202000121 [doi]
AB  - Caloric restriction (CR) is an innovative therapy used in tumor tissue and tumor 
      model studies to promote cell death and decrease cell viability. Caloric 
      restriction mimetics (CRMs) are a class of drugs that induce CR and starvation 
      conditions within a cell. When used simultaneously with other chemotherapy 
      agents, the effects are synergistic and effective at promoting tumor cell death. 
      In this review, we discuss CRMs and their potential as cancer therapeutics. 
      Firstly, we establish an overview of CR and its impacts on healthy and tumor 
      cells. CR and CRM drugs have shown to decrease age-related diseases and can act 
      as an anti-cancer agent. As it can be challenging for an individual to diligently 
      stick to a diet that would induce CR, CRMs are even more desirable. Then, we 
      discuss the drug class by highlighting three CRMs: resveratrol, (-)-hydroxycitric 
      acid, and rapamycin. These CRMs are commonly known for their dietary effects, but 
      the underlying mechanisms that drive cellular metabolic and proteomic changes 
      show promise as a cancer therapeutic. Lastly, we highlight the use of mass 
      spectrometry and proteomic techniques on experiments utilizing CRM drugs to 
      understand the cellular pathways impacted by this drug class, leading to a better 
      understanding of the anti-cancer properties and potentials of CRM.
CI  - (c) 2021 Wiley-VCH GmbH.
FAU - Bibyk, Michael J
AU  - Bibyk MJ
AD  - Ohio State Biochemistry Program, The Ohio State University, Columbus, Ohio, USA.
FAU - Campbell, Melanie J
AU  - Campbell MJ
AD  - Department of Chemistry and Biochemistry, The Ohio State University, Columbus, 
      Ohio, USA.
FAU - Hummon, Amanda B
AU  - Hummon AB
AUID- ORCID: 0000-0002-1969-9013
AD  - Ohio State Biochemistry Program, The Ohio State University, Columbus, Ohio, USA.
AD  - Department of Chemistry and Biochemistry, The Ohio State University, Columbus, 
      Ohio, USA.
AD  - The Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA.
LA  - eng
GR  - P30 CA016058/CA/NCI NIH HHS/United States
GR  - R01 GM110406/GM/NIGMS NIH HHS/United States
GR  - R01-GM110406/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
DEP - 20210223
PL  - Germany
TA  - Proteomics
JT  - Proteomics
JID - 101092707
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - *Caloric Restriction
MH  - Mass Spectrometry
MH  - *Proteomics
MH  - Sirolimus
PMC - PMC8262777
MID - NIHMS1715768
OTO - NOTNLM
OT  - anti-cancer
OT  - caloric restriction
OT  - caloric restriction mimetic
OT  - hydroxycitric acid
OT  - mass spectrometry
OT  - proteomics
OT  - rapamycin
OT  - resveratrol
COIS- CONFLICT OF INTEREST The authors declare no conflict of interest.
EDAT- 2021/01/19 06:00
MHDA- 2021/09/18 06:00
PMCR- 2022/05/01
CRDT- 2021/01/18 12:21
PHST- 2020/11/17 00:00 [revised]
PHST- 2020/08/15 00:00 [received]
PHST- 2020/12/07 00:00 [accepted]
PHST- 2021/01/19 06:00 [pubmed]
PHST- 2021/09/18 06:00 [medline]
PHST- 2021/01/18 12:21 [entrez]
PHST- 2022/05/01 00:00 [pmc-release]
AID - 10.1002/pmic.202000121 [doi]
PST - ppublish
SO  - Proteomics. 2021 May;21(9):e2000121. doi: 10.1002/pmic.202000121. Epub 2021 Feb 
      23.